469 results on '"Alanee, Shaheen"'
Search Results
2. Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment
3. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance
4. Phase I trial of intravesical Bacillus Calmette–Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette–Guérin treatment
5. Defining a “High Volume” Radical Cystectomy Hospital: Where Do We Draw the Line?
6. Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
7. Ileus and small bowel obstruction after radical cystectomy for bladder cancer: Analysis from the Nationwide Inpatient Sample
8. Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans
9. Prospective examination of the changes in the urinary microbiome induced by transrectal biopsy of the prostate using 16S rRNA gene analysis
10. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy
11. Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder
12. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer
13. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer
14. Impact of County Rurality and Urologist Density on the Practice of Inguinal Lymph Node Dissection and Mortality in Patients Diagnosed with Squamous Cell Carcinoma of the Penis
15. Impact of County Rurality and Urologist Density on Urological Cancer Mortality in Illinois
16. The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility
17. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers
18. Assessment of changes in the international prostate symptom score for patients enrolled in a phase I trial of intravesical bacillus Calmette-Guérin combined with intravenous pembrolizumab for recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous bacillus Calmette-Guérin treatment.
19. Urban-rural kidney cancer disparities: The role of health literacy, cancer literacy, smoking status, and urinary bother.
20. Machine learning-based prediction of upgrading on magnetic resonance imaging targeted biopsy in patients eligible for active surveillance
21. MP54-02 TWO-YEAR EFFICACY FOLLOW-UP OF A PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUÉRIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN RECURRENT OR PERSISTENT HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER AFTER PREVIOUS BACILLUS CALMETTE-GUÉRIN TREATMENT
22. The risk of bladder cancer in patients diagnosed with other primary neoplasms: Analysis of the SEER database
23. Partial nephrectomy for T2 renal masses: contemporary trends and oncologic efficacy
24. Complete urethral duplication: Description of surgical approach mimicking distal epispadias repair
25. Robotic‐assisted partial cystectomy for muscle invasive bladder cancer: Contemporary experience
26. Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guérin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.
27. Primary tumor size predicts pathologic findings in the retroperitoneal lymph nodes in patients with paratesticular rhabdomyosarcoma
28. List of Contributors
29. Hereditary Prostate Cancer
30. Prognostic significance of histomorphologic features of lymph node metastases in prostate cancer patients treated with radical prostatectomy: A single center study
31. PROTUMOR CONVERSION OF NATURAL KILLER CELLS BY TRANSFORMING GROWTH FACTOR-β AND HYPOXIA IN RENAL CELL CARCINOMA: MP92-04
32. First Report of ARID1A Somatic Mutation in a Female Patient With Renal Cell Carcinoma
33. Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer
34. Hyperoxaluria Is a Long-Term Consequence of Roux-en-Y Gastric Bypass: A 2-Year Prospective Longitudinal Study
35. Risk Factors and Treatment Success for Ureteral Obstruction After Pediatric Renal Transplantation
36. MP62-04 MACHINE LEARNING-BASED PREDICTION OF UPGRADING TO ADVERSE PATHOLOGY IN PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE
37. The Use of Urodynamics Assessment Before the Surgical Treatment of BPH
38. MP70-08 PARTIAL NEPHRECTOMY FOR T2 RENAL MASSES: NATIONAL TRENDS AND ONCOLOGIC EFFICACY
39. MP9-06 IMPACT OF COUNTY RURALITY AND UROLOGIST DENSITY ON UROLOGIC CANCER MORTALITY IN ILLINOIS
40. MP4-20 CONTEMPORARY INCIDENCE AND MORTALITY RATES OF NEUROENDOCRINE PROSTATE CANCER
41. Horseback Riding: Impact on Sexual Dysfunction and Lower Urinary Tract Symptoms in Men and Women
42. Contemporary Experience with Partial Nephrectomy for Stage T2 or Greater Renal Tumors
43. Genetic Factors
44. Contributors
45. Re: Peng Xu, Binshen Chen, Abai Xu, Dan Yuan, Yiming Zhang, Chunxiao Liu. Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction. Eur Urol 2021;79:545–51
46. Management of Early Prostate Cancer
47. PILOT INVESTIGATION OF VARIANTS IN DNA REPAIR PATHWAYS AND ASSOCIATION WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN BLADDER CANCER.: MP61-05
48. OUTCOME OF GENETIC EVALUATION OF KIDNEY CANCER PATIENTS REFERRED FOR SUSPECTED HEREDITARY CANCER SYNDROMES: PD10-05
49. AUTHOR REPLY
50. Editorial Comment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.